Korean J Med.  2000 Dec;59(6):674-678.

A case of acute myeloid leukemia in chronic renal failure patient on erythropoietin treatment

Affiliations
  • 1Department of Internal Medicine, College of Medicine, Hallym University, Korea.
  • 2Department of Clinical Pathology, College of Medicine, Hallym University, Korea.

Abstract

Recombinant human erythropoietin is a synthetic glycoprotein hormone and has the effect on bone marrow erythroid progenitor cells. Therefore, recombinant human erythropoietin has been frequently used as an agent treating anemia in chronic renal failure patients. However, Stockenhuber reported that recombinant human erythropoietin also affected other bone marrow progenitor cells (colony- forming unit-granulocyte-erythrocyte-macrophage, colony-forming-gra-nulocyte-macrophage). This reports may suggest a possible casual relationship between acute myeloid leukemia and erythropoietin. Acute myeloid leukemia is a rare disease in patients with chronic renal failure especially on erythropoietin treatment. By this time only a case of acute leukemia in chronic renal failure was reported by Campistrus in 1995. Campistrus's case was on the remission state of acute myeloid leukemia, and erythropoietin was administered to treat anemia of chronic renal failure. Also no previous case of acute myeloid leukemia developed in chronic renal failure patients on erythropoietin treatment was yet reported in Korea. So, we report a case of acute myeloid leukemia developed in a pre-dialysis chronic renal failure patient but on erythropoietin treatment.

Keyword

Erythropoietin; Kidney failure; Chronic; Leukemia; Myeloid

MeSH Terms

Anemia
Bone Marrow
Erythroid Precursor Cells
Erythropoietin*
Glycoproteins
Humans
Kidney Failure, Chronic*
Korea
Leukemia
Leukemia, Myeloid, Acute*
Rare Diseases
Renal Insufficiency
Stem Cells
Erythropoietin
Glycoproteins
Full Text Links
  • KJM
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr